Lexaria Bioscience Unveils Extensive Planned 2024 GLP-1 Study Program

Lexaria Bioscience Extensive Program Designed to Support Commercial Discussions.

January 16, 2024, Lexaria Bioscience (LEXX) announced a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with the global pharmaceutical companies.

Lexaria Bioscience patented drug delivery technology DehydraTECHTM . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.